Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Virdante Pharmaceuticals

Request full access

A privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders

Cambridge, United StatesFounded 2007Biotech & Life Sciences

About Virdante Pharmaceuticals

Virdante Pharmaceuticals was a biopharmaceutical firm concentrated on creating treatments for autoimmune and inflammatory diseases. The company was established in 2007, though some sources state 2008, and was previously known as Centaurus Pharmaceuticals. It was founded by Dr. Jeffrey Ravetch, a professor at The Rockefeller University, who discovered the anti-inflammatory biological pathway that formed the basis of the company's core technology. Virdante secured an exclusive license for this technology from The Rockefeller University and formed a research alliance with Dr. Ravetch's lab. To lead the commercialization efforts, John Ripple, who previously served as CEO of Syntonix Pharmaceuticals, was brought on as CEO in 2008.

The company's central technology was the proprietary "sialic switch". This technology enhances the anti-inflammatory characteristics of antibodies by adding sialic acid to them, a process known as sialylation. The primary application was to increase the potency of intravenous immunoglobulin (IVIG), a plasma-derived product used for treating autoimmune disorders. By creating a more potent version, called sIVIG, Virdante aimed to dramatically reduce the dosage and administration time for patients, from days to a matter of hours. The business model involved purchasing IVIG on the market and applying its proprietary manufacturing step to produce sIVIG. The company was also developing a second product, a sialylated recombinant Fc fragment (sFc). The firm operated in the biopharmaceutical market, specifically targeting the multi-billion dollar market for plasma-derived IVIG products and other antibody therapeutics for autoimmune and inflammatory conditions.

Virdante Pharmaceuticals successfully raised significant capital to fund its research and development. It completed a Series A funding round totaling $47.75 million and a Series B round of $30.1 million. Key investors included Thomas, McNerney & Partners, Venrock, Clarus Ventures, MedImmune Ventures, Osage University Partners, and Biogen. In December 2011, Momenta Pharmaceuticals acquired Virdante's Sialic Switch assets, including intellectual property and cell lines, for an upfront payment of $4.5 million with potential milestone payments that could total $51.5 million. Following this transaction, Virdante began operating as a subsidiary of Momenta Pharmaceuticals.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
1
Open positions
None listed
Dealroom signal
24.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Dec 2011 $52M $52M Momenta Pharmaceuticals —
LATE VCOther financing Oct 2011 $30M $120M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Virdante Pharmaceuticals website traffic

Latest recorded traffic for Virdante Pharmaceuticals is 0 monthly website visits. Virdante Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Virdante Pharmaceuticals in the Cambridge ecosystem

Live from Dealroom

The Virdante Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Venrock
  • Clarus Ventures
  • MedImmune Ventures
  • Osage University Partners
  • Biogen

Other known investors1 additional known investor

  • Momenta Pharmaceuticals
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Virdante Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Virdante Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.